The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial ensembles, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial compositions, and compositions comprising the same, in methods for modulating the agricultural production of ruminants. In particular aspects, the disclosure provides methods of increasing feed efficiency, and methods of decreasing acidosis.

The present invention relates generally to a feed supplement preparation for administration to ruminant animals and, more particularly, to a formulation for an oral bovine supplement for neonatal calves that delivers naturally occurring caffeine, in a stable liquid form of elevated viscosity and optionally antioxidants and other electrolytes. A 10-40 ml liquid dose of the supplement containing green tea extract delivers a concentrated amount of caffeine of about 100-400 mg to the neonatal calf.

The present invention relates generally to a feed supplement preparation for administration to ruminant animals and, more particularly, to a formulation for an oral bovine supplement for neonatal calves that delivers naturally occurring caffeine, in a stable liquid form of elevated viscosity and optionally antioxidants and other electrolytes. A 10-40 ml liquid dose of the supplement containing green tea extract delivers a concentrated amount of caffeine of about 100-400 mg to the neonatal calf.

The present disclosure discloses an antimicrobial peptide Scyreprocin of Scylla paramamosain and a method thereof, wherein an amino acid sequence of the antimicrobial peptide Scyreprocin comprises a sequence shown in SEQ ID NO 01, and the antimicrobial peptide is expressed and purified by using genetic engineering technology. The recombinant antimicrobial peptide Scyreprocin has advantages of wide antimicrobial spectrum, good antimicrobial effect, and rapid germicidal rate, shows great application significance, and has good application in preparation of antimicrobial agents. The recombinant antimicrobial peptide Scyreprocin has no cytotoxicity to mouse hepatocytes AML12, human liver cells L02, and can be safely used for medical treatment or can be used as a feed composition.

There is provided an agent for suppressing the insulin resistance of a ruminant, the agent including cashew nut shell liquid, heated cashew nut shell liquid, anacardic acid, cardanol, and/or cardol.

The present invention discloses application of a bile acid composite bacterial agent in the preparation of feed additives for mutton sheep. The bile acid composite bacterial agent comprises Parabacteroides distasonis bacterial suspension and bile acid, and the Parabacteroides distasonis bacterial suspension is obtained by cultivation and fermentation of Parabacteroides distasonis LCG-06 with the deposit number CGMCC No. 20820. The bile acid composite bacterial agent of the present invention has natural components and has no toxic and side effects, and can significantly increase the growth rate of mutton sheep and promote nutrition absorption, accelerate the decomposition of in vivo fat of mutton sheep, thereby reducing the body fat percentage of mutton sheep, increasing the slaughter weight and slaughter rate of mutton sheep, increasing the incomes for breeding of mutton sheep. Therefore, it has broad application prospects.

The present invention discloses application of a bile acid composite bacterial agent in the preparation of feed additives for mutton sheep. The bile acid composite bacterial agent comprises Parabacteroides distasonis bacterial suspension and bile acid, and the Parabacteroides distasonis bacterial suspension is obtained by cultivation and fermentation of Parabacteroides distasonis LCG-06 with the deposit number CGMCC No. 20820. The bile acid composite bacterial agent of the present invention has natural components and has no toxic and side effects, and can significantly increase the growth rate of mutton sheep and promote nutrition absorption, accelerate the decomposition of in vivo fat of mutton sheep, thereby reducing the body fat percentage of mutton sheep, increasing the slaughter weight and slaughter rate of mutton sheep, increasing the incomes for breeding of mutton sheep. Therefore, it has broad application prospects.

The present invention relates to a novel strain of Lactobacillus fermentum LM1016 deposited with the Korean Culture Center of Microorganisms under accession number KCCM12468P. The novel strain of the present invention has an effect of treating or preventing cardiovascular diseases, obesity, fatty liver or diabetes mellitus.

The present invention relates to a composition comprising the strain, and the composition may be used in a pharmaceutical product, a health functional food, a dairy product, a fermented product, a food additive and an animal feed and the like.

The present disclosure describes products formulated to inhibit respiratory conditions and symptoms in animals, along with associated methods of providing such products to the animals. Feeding methods involve providing animals with a feed product that includes a direct-fed microbial composition, at least one phytogenic compound, and/or at least one vitamin. The direct-fed microbial composition includes one or more strains of Bacillus. The animals can include swine or cattle at risk of developing, or already afflicted with, a respiratory condition. Inhibition of respiratory stress can reduce mortality rates and medication administration relative to animals fed the same diet but lacking the feed product.

The present disclosure describes products formulated to inhibit respiratory conditions and symptoms in animals, along with associated methods of providing such products to the animals. Feeding methods involve providing animals with a feed product that includes a direct-fed microbial composition, at least one phytogenic compound, and/or at least one vitamin. The direct-fed microbial composition includes one or more strains of Bacillus. The animals can include swine or cattle at risk of developing, or already afflicted with, a respiratory condition. Inhibition of respiratory stress can reduce mortality rates and medication administration relative to animals fed the same diet but lacking the feed product.